Data / Research funding / North Carolina / Mucommune, LLC
Mucommune, LLC: 23 NIH awards ($19.5M), fiscal years 2021 to 2026
Mucommune, LLC in Morrisville, NC is funded under 23 NIH awards ($19.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NWVPL2L4JMN8
- State
- North Carolina
Awards
23 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,380,033 | March 4, 2021 | February 28, 2026 | CONE, RICHARD | reporter.nih.gov |
| IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $2,067,567 | September 19, 2022 | August 31, 2025 | CONE, RICHARD | reporter.nih.gov |
| Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,702,035 | April 1, 2021 | March 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,622,042 | September 14, 2019 | August 31, 2025 | MOENCH, THOMAS RAY | reporter.nih.gov |
| Development of RespiraClear for targeted mucosal treatment of RSV infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,549,957 | August 19, 2019 | April 30, 2024 | CONE, RICHARD | reporter.nih.gov |
| SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma | NIH | National Cancer Institute | 2025 | $1,146,618 | September 16, 2025 | August 31, 2027 | YANG, MING | reporter.nih.gov |
| Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $1,130,880 | September 15, 2025 | August 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy | NIH | National Cancer Institute | 2025 | $1,031,566 | September 11, 2025 | August 31, 2027 | YANG, MING | reporter.nih.gov |
| IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,025,000 | June 23, 2025 | May 31, 2028 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $995,652 | August 20, 2018 | November 30, 2022 | CONE, RICHARD | reporter.nih.gov |
| In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $756,985 | September 15, 2020 | August 31, 2023 | CONE, RICHARD | reporter.nih.gov |
| IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $582,916 | January 22, 2024 | December 31, 2026 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia | NIH | National Cancer Institute | 2025 | $409,732 | September 12, 2025 | August 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $380,692 | March 25, 2025 | February 28, 2026 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $359,608 | September 15, 2025 | August 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $310,136 | August 21, 2025 | July 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $306,500 | March 1, 2021 | February 28, 2023 | CONE, RICHARD | reporter.nih.gov |
| Fast dissolving antibody tablets for preventing vaginal HSV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $306,500 | September 1, 2022 | August 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $306,483 | April 1, 2023 | March 31, 2025 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Sustained release of VRC07 from capsule-intravaginal ring for preventing HIV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $306,183 | July 1, 2025 | June 30, 2026 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $277,713 | July 1, 2022 | June 30, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $265,970 | August 1, 2021 | July 31, 2023 | CONE, RICHARD | reporter.nih.gov |
| User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $259,499 | September 1, 2022 | August 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 10 | $6,391,873 | 0 | $0 |
| 2024 | 2 | $1,328,507 | 0 | $0 |
| 2023 | 4 | $2,907,384 | 0 | $0 |
| 2022 | 7 | $4,106,225 | 0 | $0 |
| 2021 | 8 | $4,746,278 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Autism Centers of Excellence R01 | RFA-HD-27-001 | NIH | 93.865 | November 2, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Autism Centers of Excellence P50 | RFA-HD-27-002 | NIH | 93.865 | November 2, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 9 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 9 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.865 | November 16, 2026 | $50,000 | Same assistance listing 93.865 as 9 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.865 | November 18, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.865 | November 18, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.865 | November 23, 2026 | $375,000 | Same assistance listing 93.865 as 9 awards here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.865 | November 24, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.865 | December 4, 2026 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.865 | January 5, 2027 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.865 | January 5, 2027 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.865 | January 7, 2027 | $375,000 | Same assistance listing 93.865 as 9 awards here |
| Intervention Research to Improve Native American Health (R34 Clinical Trial Optional) | PAR-25-378 | NIH | 93.865 | January 7, 2027 | Not listed | Same assistance listing 93.865 as 9 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.865 | January 7, 2027 | Not listed | Same assistance listing 93.865 as 9 awards here |
| HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) | RFA-NS-25-023 | NIH | 93.865 | January 15, 2027 | $350,000 | Same assistance listing 93.865 as 9 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 9 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 9 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 9 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 9 awards here |
Topics of its NIH awards
- Prevention
- Biotechnology
- Clinical Research
- Infectious Diseases
- Contraception/Reproduction
- Immunization
- Sexually Transmitted Infections
- Women's Health
- Translational Research
- Topical Microbicides
- Bioengineering
- Women's Health Research
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.